U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07351045) titled 'A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes' on Jan. 16.
Brief Summary: The purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Obesity or Overweight
Intervention: ...